|
In our continuing efforts to provide the most advanced technology and
highest quality care available to our patients, this practice is proud to
announce the inclusion to the
ViziLite exam as an integral part of our annual comprehensive oral cancer screening.
One person dies every hour from oral cancer in the
Unites States - and the mortality has remained unchanged for more than
40 years. Alarmingly, more than 25% of oral cancer victims have no
lifestyle risk factors. Clinical studies have determined that
using ViziLite after the standard oral cancer examination
improves the clinician's ability to identify, evaluate and monitor
suspicious areas at their earliest stages. Early detection of
pre-cancerous tissue can minimize or eliminate the potentially
disfiguring effects of oral cancer and possibly save your life.
Proven screening technologies such as mammogram, Pap smear, PSA and
colonoscopy offer the same types of early detection of cancer. ViziLite
is an easy and painless examination that gives this practice the best
chance to find any oral abnormalities you may have at the earliest
possible stage. This technology is the only FDA-cleared device for the
indentification and monitoring of oral abnormalities that could lead to
cancer.
Oral cancer risk by patient profile is listed
below:
Highest Risk: Patients age 40 and older and
lifestyle risk factors (tobacco use); patients with a history of oral
cancer
High Risk: Patients age 40 and older; tobacco
users of any age
Increased Risk: Patients age 18 - 39
Dental Insurance might not cover this advanced
oral cancer screening as an addition to the standard visual examination.
This practice prescribes the ViziLite exam for all patients
at increased risk, high risk and highest risk for oral cancer (adult
patients age 18 and older and tobacco users of any age). We will
be performing the ViziLite exam following the standard oral
cancer examination of the oral cavity for a fee.
ViziLite® Plus oral lesion identification and marking system
The newest tool in the fight against oral disease is the ViziLite® Plus oral lesion identification and marking system.
ViziLite® Plus, from Zila Pharmaceuticals, combines the oral screening technology of ViziLite, an advanced chemiluminescent light technology to help detect oral abnormalities, with TBlue630™. TBlue630 is the only patented pharmaceutical-grade form of toluidine blue that has been cleared by the FDA for use in marking lesions identified during a ViziLite examination.
ViziLite Plus makes oral screening more comprehensive than ever before and is indicated for use in individuals at increased risk of oral cancer. If ViziLite reveals an abnormality, TBlue630 can be used to mark suspicious lesions for further evaluation.
For more information about Zila, visit
www.zila.com
Click here to view the Vizilite Brochure |
